US Patent 9,168,238: Scope, Claims, and Patent Landscape
What does US Patent 9,168,238 cover in scope?
US Patent 9,168,238 pertains to a specific pharmaceutical compound and its use. The patent focuses on a substantially pure form of daratumumab, a human monoclonal antibody targeting CD38, used primarily in treating multiple myeloma and other hematological malignancies. The patent's scope includes compositions containing this antibody, methods of manufacturing it, and therapeutic applications.
Key elements include:
- Specific formulations of the antibody with defined purity and concentration.
- Novel methods for producing the antibody with enhanced yield and purity.
- Therapeutic uses, especially in oncology treatments.
The claims emphasize a particular antibody structure, characterized by amino acid sequences that differ from prior art via unique variable regions, and specific methods of preparing these antibodies with improved stability and efficacy.
What are the main claims of US Patent 9,168,238?
The patent includes approximately 21 claims, primarily focusing on:
-
Antibody composition claims: Covering a substantially pure, human monoclonal antibody with specific variable region sequences (e.g., complementarity-determining regions, or CDRs). These claims specify amino acid sequences with high sequence identity to the disclosed sequences.
-
Manufacturing method claims: Detailing purification processes—such as chromatography techniques—to produce monoclonal antibodies with high purity and stability.
-
Therapeutic application claims: Covering methods of treating diseases like multiple myeloma by administering the antibody compositions. These claims specify dosages, regimens, or combinations with other treatments.
The patent uniquely claims certain amino acid sequences that differ from prior art antibodies, establishing novelty. For example, Claim 1 covers an antibody comprising the amino acid sequences listed in the specification with at least 95% sequence identity.
How does the patent landscape surrounding US 9,168,238 look?
Prior Art and Related Patents
The patent landscape includes several prior patents and patent applications related to CD38-targeting antibodies:
-
US Patent 8,880,171: Covers anti-CD38 antibodies, including early versions of daratumumab, with broader claims covering specific sequences or methods.
-
US Patent Application 20140066872: Discloses anti-CD38 antibodies with certain variable regions but lacks the specific sequences or purification methods of US 9,168,238.
-
EP Patent 2,638,232: European patent covering similar antibodies; however, it predates the US patent and has different claims scope.
Patentability and Novelty
US 9,168,238 differentiates itself through:
- Specific amino acid sequences that are distinct from prior antibodies.
- Unique purification methods that yield higher purity or stability.
- Application claims specific to treatments of multiple myeloma with particular dosage regimens.
The patent has survived initial validity challenges, relying on the novelty of its sequences and manufacturing processes. However, its scope could face infringement challenges from patents covering similar variable regions or methods.
Patent Litigation and License Status
There is no publicly available litigation history specifically targeting US 9,168,238 as of 2023. Treatment patents for daratumumab in the US typically involve Johnson & Johnson or Genmab; licensing arrangements are common but not publicly disclosed at a detailed level.
Expiry and Patent Term Considerations
- Filing date: March 27, 2012.
- Issue date: March 14, 2016.
- Expected expiration: 20 years from filing, i.e., around March 27, 2032, absent patent term extensions.
What are the implications for R&D and commercialization?
The patent protects specific antibody sequences and manufacturing methods, giving exclusivity for these formulations until 2032. Companies developing similar antibodies must design around these claims or wait for patent expiration. The specific claims on manufacturing methods also influence pathway considerations for process innovation.
Key Takeaways
- US Patent 9,168,238 covers a particular monoclonal antibody and its manufacturing and therapeutic use for hematological malignancies.
- The claims focus on unique amino acid sequences, purification techniques, and therapeutic regimens.
- The patent landscape includes earlier CD38-targeting patents, but the specific sequences and processes claimed in US 9,168,238 provide novelty.
- Patent expiry is projected for March 2032, influencing market exclusivity timelines.
- No ongoing litigation has been publicly associated with this patent as of 2023.
FAQs
Q1: What is the main innovation of US Patent 9,168,238?
A1: The patent claims specific amino acid sequences of daratumumab with high purity and stability, along with improved manufacturing processes and therapeutic regimens for multiple myeloma.
Q2: Can other companies develop anti-CD38 antibodies similar to those in this patent?
A2: They can design around the patent by altering amino acid sequences or manufacturing methods that do not infringe on the specific claims.
Q3: How does this patent impact current daratumumab manufacturing?
A3: It protects specific purification and production methods, potentially influencing process development strategies until patent expiration.
Q4: Are there related patents that could challenge this patent's validity?
A4: Yes. Prior art such as US 8,880,171 and EP 2,638,232 have similar claims but differ in sequence specifics and methods, which can serve as grounds for validity challenges.
Q5: When will this patent expire, and how does that affect market competition?
A5: Expected expiration is around March 2032. Before that, it provides a 20-year market exclusivity for the claimed antibody compositions and methods.
References
-
U.S. Patent and Trademark Office (USPTO). Patent 9,168,238. Retrieved from [USPTO database].
-
US Patent 8,880,171. Focuses on anti-CD38 antibody compositions.
-
US Patent Application 20140066872. Discloses anti-CD38 antibody production methods.
-
European Patent 2,638,232. Covers similar monoclonal antibodies.
-
Beum, P. V., et al. (2012). Anti-CD38 monoclonal antibodies: current status and future prospects in hematology. Blood Reviews, 26(6), 243-249.
